Research Article
Hypochlorous Acid Can Be the Novel Option for the Meibomian Gland Dysfunction Dry Eye through Ultrasonic Atomization
Table 2
Summary of efficacy endpoints between hypochlorous acid (HOCL) and placebo groups.
| Visit duration | HOCL (), | Placebo (), | value by ANOVA for HOCL vs. placebo |
| (a) Ocular surface disease index (OSDI) scores | | | | 1st day | | | 0.058 | 15th day | | | 0.061 | 30th day | | | 0.055 | 55th day | | | 0.052 | (b) Schirmer’s test average of both eyes | | | | 1st day | | | 0.411 | 15th day | | | 0.053 | 30th day | | | <0.05 | 55th day | | | <0.01 | (c) Tear film break-up time (TBUT) average of both eyes | | | | 1st day | | | 0.423 | 15th day | | | 0.351 | 30th day | | | 0.459 | 55th day | | | <0.05 | (d) Conjunctivae labeling average of both eyes | | | | 1st day | | | 0.677 | 55th day | | | <0.01 | (e) Corneal labeling average of both eyes | | | | 1st day | | | 0.406 | 55th day | | | <0.05 |
|
|